

Jonathan D Schoenfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4846432/publications.pdf>

Version: 2024-02-01

103
papers

4,738
citations

136950

32
h-index

118850

62
g-index

106
all docs

106
docs citations

106
times ranked

7412
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant and Adjuvant Nivolumab and Liriumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 468-478.	7.0	45
2	Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.		14
3	Technical note: Toward implementation of MR-guided radiation therapy for laryngeal cancer with healthy volunteer imaging and a custom MR-CT larynx phantom. <i>Medical Physics</i> , 2022, 49, 1814-1821.	3.0	4
4	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 279-291.	10.7	118
5	Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors. <i>Advances in Radiation Oncology</i> , 2022, 7, 100880.	1.2	3
6	Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. <i>Future Oncology</i> , 2022, 18, 1669-1678.	2.4	15
7	Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 87-94.	1.2	14
8	Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. <i>Head and Neck</i> , 2022, , .	2.0	3
9	Use of Fluoro- ¹⁸ F-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 268.	2.2	3
10	Unusual presentation of HPV-positive squamous cell carcinoma of the nasolacrimal duct as carcinoma of unknown primary. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2022, 43, 103457.	1.3	0
11	Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. <i>Head and Neck</i> , 2022, 44, 722-734.	2.0	6
12	Imaging features, therapies, and outcomes of fibrosing inflammatory pseudotumor of the nasopharynx: A systematic review. <i>Journal of Neuroimaging</i> , 2022, 32, 223-229.	2.0	1
13	Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. <i>Cell</i> , 2022, 185, 2918-2935.e29.	28.9	113
14	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.8	61
15	Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. <i>Oral Oncology</i> , 2021, 112, 105087.	1.5	8
16	Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 875-877.	1.2	3
17	Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. <i>Advances in Radiation Oncology</i> , 2021, 6, 100608.	1.2	2
18	NUT Carcinoma of the Thyroid: An Unusual Case with a Complete Response to Treatment. <i>Clinical Thyroidology</i> , 2021, 33, 38-47.	0.1	9

#	ARTICLE	IF	CITATIONS
19	Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumabâ€”Reply. <i>JAMA Oncology</i> , 2021, 7, 309.	7.1	1
20	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2470-2480.	7.0	51
21	The effects of releasing early results from ongoing clinical trials. <i>Nature Communications</i> , 2021, 12, 801.	12.8	4
22	Personalized Radiation Attenuating Materials for Gastrointestinal Mucosal Protection. <i>Advanced Science</i> , 2021, 8, 2100510.	11.2	3
23	Reply to â€œKeynote 48: Is it really for everyone?â€œ. <i>Oral Oncology</i> , 2021, 115, 105108.	1.5	0
24	Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. , 2021, 9, e002038.		124
25	Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6053-6053.	1.6	7
26	Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1165-1175.	0.8	8
27	Long-term Overall Survival and Predictors in Antiâ€”PD-1-naïve Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. <i>Journal of Immunotherapy</i> , 2021, 44, 307-318.	2.4	4
28	Oral immuneâ€”related adverse events associated with PDâ€”1 inhibitor therapy: A case series. <i>Oral Diseases</i> , 2020, 26, 325-333.	3.0	33
29	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 1196-1206.	3.0	9
30	Radiation-Induced Hypothyroidism in Patients with Oropharyngeal Cancer Treated with IMRT: Independent and External Validation of Five Normal Tissue Complication Probability Models. <i>Cancers</i> , 2020, 12, 2716.	3.7	5
31	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for nonâ€”small cell lung cancer and melanoma brain metastases. <i>Cancer</i> , 2020, 126, 5274-5282.	4.1	19
32	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirusâ€”Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5140-5152.	7.0	163
33	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 238-245.	2.4	44
34	Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. <i>Head and Neck</i> , 2020, 42, 3670-3677.	2.0	3
35	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1563.	7.1	198
36	Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. <i>World Neurosurgery</i> , 2020, 139, 226-231.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Keynote 48: Is it really for everyone?. Oral Oncology, 2020, 105, 104762.	1.5	8
38	Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer, 2020, 126, 1424-1433.	4.1	20
39	Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2020, 105, 104676.	1.5	16
40	The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist, 2020, 25, 598-608.	3.7	26
41	Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncology, 2020, 106, 104690.	1.5	21
42	Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges. Frontiers in Oncology, 2020, 10, 608772.	2.8	30
43	Radiosensitizers in the Era of Immuno-Oncology. Cancer Drug Discovery and Development, 2020, , 339-360.	0.4	0
44	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1660-1667.	2.5	127
45	A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2019, 105, 132-139.	0.8	8
46	PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S139-S146.	2.8	11
47	Radiation Therapy and Immune Modulation. Hematology/Oncology Clinics of North America, 2019, 33, 233-248.	2.2	6
48	Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence. Head and Neck, 2019, 41, 2111-2115.	2.0	4
49	Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. , 2019, 7, 112.		69
50	Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Frontiers in Oncology, 2019, 9, 199.	2.8	9
51	Everolimus in Anaplastic Thyroid Cancer: A Case Series. Frontiers in Oncology, 2019, 9, 106.	2.8	25
52	Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. , 2019, 7, 89.		108
53	Immunotherapy and radiotherapy for metastatic cancers. Annals of Palliative Medicine, 2019, 8, 312-325.	1.2	33
54	Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer—A Perspective on Future Trial Designs. Clinical Cancer Research, 2019, 25, 7281-7286.	7.0	19

#	ARTICLE	IF	CITATIONS
55	Immunotherapy and Radiation. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 1057-1069.	2.2	2
56	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 142-151.	0.8	118
57	IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. <i>Head and Neck</i> , 2019, 41, 959-966.	2.0	8
58	Using immunotherapy to boost the abscopal effect. <i>Nature Reviews Cancer</i> , 2018, 18, 313-322.	28.4	844
59	Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1259-1270.	0.8	54
60	Hazards of Hazard Ratios – Deviations from Model Assumptions in Immunotherapy. <i>New England Journal of Medicine</i> , 2018, 378, 1158-1159.	27.0	79
61	Frameshift events predict anti-PD-1/L1 response in head and neck cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	190
62	Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies. <i>Clinical Chemistry</i> , 2018, 64, 1762-1771.	3.2	21
63	We Are All Connected: Modeling the Tumor-Immune Ecosystem. <i>Trends in Cancer</i> , 2018, 4, 655-657.	7.4	8
64	Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 34-43.	0.8	9
65	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 137-145.	0.8	24
66	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 85, 29-34.	1.5	15
67	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 67, 61-69.	1.5	42
68	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017, 22, 343-350.	3.7	57
69	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 344-351.	0.8	143
70	Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. <i>Cancer Biomarkers</i> , 2017, 19, 129-136.	1.7	22
71	Prospective analysis of radiation oncology image and plan-driven peer review for head and neck cancer. <i>Head and Neck</i> , 2017, 39, 1603-1608.	2.0	9
72	Potential Role of the Quality Assurance Review Center Platform in Global Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 956-962.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 98-103.	0.6	51
74	Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 191.	2.8	42
75	Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. <i>BJR case Reports</i> , 2016, 2, 20150271.	0.2	3
76	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. , 2016, 4, 32.		17
77	Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, 1530-1538.	2.0	9
78	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016, 115, 252-260.	6.4	66
79	Merkel Cell Carcinoma: A Population Analysis on Survival. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1247-1257.	4.9	57
80	Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. <i>Oral Oncology</i> , 2016, 61, 19-26.	1.5	20
81	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	3.4	81
82	The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 243-247.	1.3	5
83	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2939-2949.	7.0	51
84	Radiation dose and checkpoint blockade immunotherapy: unanswered questions. <i>Lancet Oncology</i> , The, 2016, 17, e3-e4.	10.7	9
85	Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. , 2015, 3, 50.		84
86	Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. <i>Cancer</i> , 2015, 121, 2594-2602.	4.1	53
87	Ensuring Head and Neck Oncology Patients Receive Recommended Pretreatment Dental Evaluations. <i>Journal of Oncology Practice</i> , 2015, 11, 151-154.	2.5	8
88	Immunity in Head and Neck Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 12-17.	3.4	53
89	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. <i>Oncolimmunology</i> , 2015, 4, e1046028.	4.6	191
90	Immune effects of targeted radiation therapy for cancer. <i>Discovery Medicine</i> , 2015, 19, 219-28.	0.5	24

#	ARTICLE	IF	CITATIONS
91	Is everything we eat associated with cancer? A systematic cookbook review. American Journal of Clinical Nutrition, 2013, 97, 127-134.	4.7	165
92	A Single Nucleotide Polymorphism in Inflammatory Gene <i>RNASEL</i> Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. Clinical Cancer Research, 2013, 19, 1612-1619.	7.0	20
93	Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome. Annals of Oncology, 2012, 23, 1813-1818.	1.2	26
94	Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 308-314.	0.8	104
95	PET/CT of Cancer Patients: Part 2, Deformable Registration Imaging Before and After Chemotherapy for Radiation Treatment Planning in Head and Neck Cancer. American Journal of Roentgenology, 2012, 199, 968-974.	2.2	8
96	Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib—a case report. Anticancer Research, 2012, 32, 1743-6.	1.1	15
97	Abbreviated course of radiotherapy (RT) for breast cancer. Breast, 2011, 20, S116-S127.	2.2	16
98	Anti-angiogenesis immunotherapy. Hum Vaccin, 2011, 7, 976-981.	2.4	17
99	Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis. Cancer Research, 2010, 70, 10150-10160.	0.9	69
100	PECAM-1 Affects GSK-3 β -Mediated β -Catenin Phosphorylation and Degradation. American Journal of Pathology, 2006, 169, 314-324.	3.8	77
101	Identification of the regions of PECAM-1 involved in β - and γ -catenin associations. Biochemical and Biophysical Research Communications, 2005, 329, 1225-1233.	2.1	27
102	Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF. Angiogenesis, 2004, 7, 143-156.	7.2	29
103	PECAM-1 promotes β -catenin accumulation and stimulates endothelial cell proliferation. Biochemical and Biophysical Research Communications, 2003, 303, 212-218.	2.1	42